CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation

Tachycardia, Ventricular Clinical Trial

Official title:

CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02661048
• Other study ID #: CyberHeart Inc. -001
• Status: Completed
• Phase: N/A
• Start date: February 27, 2015
• Est. completion date: July 6, 2023

Study information

• Verified date: September 2023
• Source: Varian, a Siemens Healthineers Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical investigation is to evaluate:

1. the safety and efficacy of the CyberHeart System, CardioPlan™ Software and Laptop, in treating patients with refractory ventricular tachycardia (VT) using the CyberKnife® Radiosurgical System.

2. The CyberHeart System performance with respect to the ability to contour myocardial targets that are transferred to the Multi-plan® Treatment Planning Software of the CyberKnife® system for the production and delivery of a safe radiosurgical treatment plan.

Cardiac radiosurgery is a minimally-non invasive, painless, procedure. Tissue ablation can be accomplished precisely.

Description:

This study is a prospective, multi-center (2), single arm, open label US-based feasibility study.

The clinical hypothesis for the study is that the CyberHeart treatment approach will be safe and with further study will not be shown to be inferior to current treatment options, may lead to a survival benefit and improved quality of life.

The ablation to be performed with the CyberHeart System will be targeting the anatomical site of the clinically presenting VT. The application site will be determined by morphological criteria on the 12 lead ECG along with anatomical data from MRI or CT scan imaging. Ablation will be performed at the designated location with the intention to produce substrate modification.

The Study will enroll a maximum of 10 patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: July 6, 2023
• Est. primary completion date: July 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Presence of an implantable cardioverter-defibrillator (ICD)

• Patients with ischemic or non-ischemic cardiomyopathy who have had recurrent symptomatic VT that induced ICD shock(s) following catheter ablation and/or antiarrhythmic drug (AAD) therapy.

• 60 years of age or greater.

• Left ventricular ejection fraction = 20%.

• Failure of or ineligible for catheter ablation.

Exclusion Criteria:

• Unable or unwilling to provide informed consent

• Patients with idiopathic VT

• Women who are pregnant

• Prior radiation therapy to the thorax

• Active ischemia or other reversible causes of VT

• Active non-cardiovascular illness or systemic infection

• Presence of thrombus in the right atrium or right ventricle on pre-procedure echocardiogram

• Cardiogenic shock

• NYHA (New York Heart Association) Class IV Heart Failure.

• Presence of incessant VT that is hemodynamically unstable.

• Acute heart failure exacerbation.

• Revascularization in the past 90 days.

• Other disease process that is likely to limit survival to less than 12 months

Related Conditions & MeSH terms

• Arrhythmias, Cardiac
• Tachycardia
• Tachycardia, Ventricular

Intervention

Device:
• CyberHeart System
The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation

Locations

Country	Name	City	State
United States	Texas Cardiac Arrhythmia Research Foundation	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Varian, a Siemens Healthineers Company

Country where clinical trial is conducted

United States, 

References & Publications (1)

Loo BW Jr, Soltys SG, Wang L, Lo A, Fahimian BP, Iagaru A, Norton L, Shan X, Gardner E, Fogarty T, Maguire P, Al-Ahmad A, Zei P. Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia. Circ Arrhythm Electrophysio — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Outcome 1 is the Number of participants with Treatment related Serious Adverse Events as assessed by CTCAE v. 4.0	Outcome 1 is measured by The number of Participants, and the percentage of participants with : - Serious Adverse Events; (1) in the first 30 days, (2) in days 31 to 1 year post treatment, both treatment related, and non-treatment related, separately tabulated.	12 months (360 days) with Outcome assesment in first 30 days adn in days 31 to 1 year post treatment.
Secondary	Number of participants with a change in SF-36 Medical Outcomes Health Survey, as compared to pre-treatment questionaire responses	Participants will complete a SF-36 (Short Form-36) Medical Outcomes Survey before treatment and at each post treatment follow-up check. Absolute numeric numbers will be tabulated and percentage change will be calculated	12 months
Secondary	Number of defibrillation shocks as compared to pretreatment occurrence	Defibrillation shocks will be recorded pre-treatment and post treatment at each follow-up visit.	12 months
Secondary	Ventricular arrhythmia episodes, as compared to pretreatment occurrence	The number of ventricular tachycardia episodes that required either anti-tachycardia pacing, or that self-terminated, will be recorded pre- and post treatment.	12 months
Secondary	Left ventricular function post treatment	Left ventricular systolic and diastolic function will be assessed by echocardiography pre- and post treatment	12 months